ArticleFrontiers in oncology2023

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001).

Bo Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.